Jounce Therapeutics, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Revenue:
License and collaboration revenue—related party
Operating expenses:
Research and development
General and administrative
Total operating expenses
Operating loss
Other income, net
Loss before provision for income taxes
Provision for income taxes
Net loss
Accrued dividends on convertible preferred stock
Net loss attributable to common stockholders
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)
Weighted-average common shares outstanding, basic and diluted (in shares)
Other comprehensive loss:
Unrealized loss on available-for-sale securities
Comprehensive loss
Net loss per share, basic (in dollars per share)
Net loss per share, diluted (in dollars per share)
Weighted-average common shares outstanding, basic (in shares)
Weighted-average common shares outstanding, diluted (in shares)

Comments